# Stem cells weekly evidence review - November 16, 2026 Decision: substantive public update warranted. Add a qualified sickle-cell development milestone, a small diabetic-foot study, a controlled topical-formulation study and a clearly labelled catch-up FDA safety warning. Preserve the original report and earlier updates. Access date: 2026-11-16 PST, checked with the system clock. Previous review: November 9. Primary monitoring window: November 10-16; earlier material newly verified is explicitly identified as catch-up. Publication, indexing, press-release and regulatory dates are not interchangeable. This is targeted monitoring, not a systematic review or a comprehensive global approval/license audit. Article: https://managingexpectations.net/blog/articles/stem-cells-evidence-costs-risks-global-guide.html ## 1. Sickle-cell disease: company-reported BEACON milestone, not approval Primary company source, November 10: https://investors.beamtx.com/news-releases/news-release-details/beam-therapeutics-announces-positive-topline-pivotal-data-beacon Registry: https://clinicaltrials.gov/study/NCT05456880 https://clinicaltrials.gov/api/v2/studies/NCT05456880 Beam reports that its open-label, single-arm phase 1/2 BEACON trial of ristoglogene autogetemcel (risto-cel, formerly BEAM-101) met its primary endpoint of freedom from severe vaso-occlusive crises for at least 12 consecutive months, and its prespecified primary safety endpoints. The product uses a patient's base-edited blood-forming stem/progenitor cells. As of the company's October 20 data cutoff, 39 adults and 10 adolescents had been treated; 31 had sufficient follow-up for the primary efficacy assessment. Important limitation: 31 is the number with sufficient follow-up, NOT a disclosed responder numerator. The release does not provide a numerical responder rate, confidence interval or detailed adverse-event table. Do not write '31 of 31 succeeded' or imply every treated participant had a year free of crises. Meeting safety endpoints does not mean no adverse events. Beam places safety findings in the context of collection, conditioning, transplantation and underlying disease. It plans a licensing application as early as year-end and detailed pivotal presentation in 2027; neither is an accomplished approval. The registry confirms the study identity and single-group/open-label design, but its last posted update is December 16, 2025, with an older estimated enrollment of 15 and no posted results. It is therefore not independent confirmation of the November outcome or enrollment counts. Do not substitute the stale registry estimate for the newer company-reported treated population. Access: direct company request returned 403; alternate web extraction recovered the full release. Registry API retrieved directly. Evidence label: company-reported clinical development milestone; promising/under study. Not a peer-reviewed pivotal-results publication, comparison against existing therapies, cure guarantee or marketing authorization. ## 2. Diabetic foot ulcers: promising small uncontrolled study Michael H Carstens, Arlen Beatriz Rios, Juan Sevilla, Carlos Rivera, Osman Pravia, Dorian Calero, Samuel Vilchez, Kenneth A Bertram and Anthony Atala. 'Treatment of diabetic foot chronic ulcers and neuropathy with placenta-derived stem cells.' Stem Cells Translational Medicine, November 3, 2026. DOI 10.1093/stcltm/szag085; PMID 42976200; PMCID PMC13730048. https://pmc.ncbi.nlm.nih.gov/articles/PMC13730048/ https://pubmed.ncbi.nlm.nih.gov/42976200/ https://doi.org/10.1093/stcltm/szag085 November 12 institutional announcement, the current-week discovery lead: https://newsroom.wakehealth.edu/news-releases/2026/11/pilot-study-tests-cell-therapy-for-difficult-to-heal-diabetic-foot-ulcers Registry: https://clinicaltrials.gov/study/NCT06373809 https://clinicaltrials.gov/api/v2/studies/NCT06373809 Full PMC paper and registry retrieved; Oxford publisher blocked access. The paper reports ten adults in Nicaragua with chronic diabetic foot ulcers, treated with a placenta-derived cell preparation. All ten wounds closed by six months; nine participants had normal protective sensation at twelve months. No treatment-related serious adverse events were reported. The study did not establish a clear overall vascular-flow benefit. Limitations from the paper's Discussion: small study, no control group, no blinding; efficacy is hypothesis-generating and rare harms cannot be excluded. Do not repeat its abstract's unqualified 'is safe' conclusion as a general safety guarantee. Wound closure is not proof of curing diabetes or of insulin-producing cell replacement. The paper states sponsorship by Nicaragua's Ministry of Health, no outside funding and no declared potential conflicts. The institutional release reports ministry approval; the original authorization document was not independently obtained. Registry appraisal: the broader record lists 20 actual participants and two groups, whereas this paper reports ten ulcer participants. Do not silently equate those denominators. The record was first posted April 18, 2024, after its listed March 31, 2024 study completion; prospective registration is therefore not established. There are no registry-posted results. These issues call for the protocol and complete cohort reporting, not an unsupported accusation of misconduct. Evidence label: promising/under study, first-in-human uncontrolled evidence. Public wording dates the November 12 announcement and identifies the November 3 paper, rather than claiming a new November 12 trial publication. No medical-tourism endorsement. ## 3. Topical 'exosome' scar products: observer benefit is not an exosome-specific effect Jun Ho Park, Jei Youn Park and Ji-Ung Park. 'Exosome-based topical formulations as adjuncts to fractional Nd: YAG laser for postoperative facial scars.' Lasers in Medical Science, November 14, 2026;41:296. DOI 10.1007/s10103-026-05098-7; PMID 43033286; PMCID PMC13769748. https://pmc.ncbi.nlm.nih.gov/articles/PMC13769748/ https://pubmed.ncbi.nlm.nih.gov/43033286/ https://doi.org/10.1007/s10103-026-05098-7 Full PMC paper and NCBI XML retrieved. Randomized allocation of 150 patients to laser plus control hydrogel, human-derived formulation or plant-derived formulation. Eleven were lost to follow-up; the complete-case analysis included 139. At the short assessment two weeks after the final treatment session, the adjunct groups improved more on clinician-rated scar measures and an exploratory optical measure. The patient-reported scale did not show a significant additional treatment effect. No serious adverse events were reported during the observed period; two transient burning events were reported in the human-derived group. Methods clarify that the products are complete formulations, not purified exosomes, and manufacturer processing descriptions were not independently verified. Particle measurements did not establish vesicular identity, purity or exosomal biogenesis. Consequently this trial cannot isolate an exosome-specific mechanism, establish long-term safety or support injected/infused exosome products. The human-versus-plant nonsignificant comparison does not establish equivalence. The Ethics declaration explicitly states that this randomized trial was not prospectively registered. The paper reports institutional research funding and no competing interests. Reporting caveats requiring clarification: the paper acknowledges attrition but also says all patients completed the full protocol; its data-availability statement says no datasets were generated or analysed despite reporting a clinical trial. These apparent reporting inconsistencies do not establish fraud, but prevent treating the report as a fully audited efficacy record. The public paragraph keeps the complete-case limitation and does not claim regulatory approval or offer product recommendations. Evidence label: promising, formulation-specific short-term randomized evidence, with reporting limitations. Not proof of general rejuvenation, scar regeneration or safety of commercial exosome injections. ## 4. Catch-up safety warning: AAV gene therapy is not stem-cell transplantation Official FDA safety communication, November 6 (not a new November 16 warning): https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-investigating-serious-risk-malignancy-linked-zolgensma-gene-therapy Index: https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/2026-safety-and-availability-communications FDA reports postmarketing malignancies after Zolgensma, including molecularly confirmed vector integration associated with oncogenesis. It applies the risk concern to Zolgensma and Itvisma because they share the vector and construct, while stating no neoplasia cases following Itvisma had been reported to date. Crucially, FDA says the overall benefits of both products continue to outweigh their potential risks for approved uses and is assessing whether regulatory action is appropriate. These are AAV-vector gene therapies for spinal muscular atrophy, not stem-cell products. Included as a clearly bounded safety follow-up because this report discusses the wider cellular/gene-therapy category; the finding must not be attributed to all stem-cell treatments, base editing or all exosomes. Do not describe the communication as a recall, withdrawal or instruction to stop treatment. Access: official safety index retrieved directly. Direct warning request hit FDA abuse-detection 404; alternate extraction recovered the full official warning. Last week's source note explicitly recorded inability to check that index. This is now-verified catch-up, not a claim that the November 9 review had already covered it. Evidence label: official postmarketing safety warning; product-specific risk and ongoing regulatory evaluation. Suggested public wording includes both the risk and FDA's continuing benefit-risk assessment. ## Required-source checks and unchanged conclusions ### FDA Approved product inventory: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products Consumer information: https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/important-patient-and-consumer-information-about-regenerative-medicine-therapies Guidance inventory: https://www.fda.gov/vaccines-blood-biologics/biologics-guidances/cellular-gene-therapy-guidances All three pages retrieved directly. Approved list is marked October 30, 2026; no newly verified stem-cell approval selected from this week's review. Risto-cel's company release continues to identify it as investigational. The November potency-assurance guidance is already covered in the November 9 update; no duplicate headline. The June 2021 consumer page supports caution about unapproved products and misleading trial/registration claims, but its historic 'only cord blood' wording is not a current inventory of approvals. See current licensed-product list instead. ### Health Canada https://www.canada.ca/en/health-canada/services/drugs-health-products/biologics-radiopharmaceuticals-genetic-therapies/applications-submissions/guidance-documents/cell-therapy-policy.html https://recalls-rappels.canada.ca/en/alert-recall/health-canada-advising-canadians-about-potential-health-risks-associated-unauthorized Both retrieved directly. Advisory remains dated May 15, 2019, not a new warning; its historical product count is not today's approval inventory. Autologous origin does not remove product risks or automatically exempt a therapy from regulation. A narrow November search was empty; a broader current search returned general clinical-trial guidance, older CAR-T safety material and a secondary July pediatric-reliance story. None established a new cell-specific Canadian change in this week's window. Canada row unchanged; no exhaustive Drug Product Database audit claimed. ### NIH/NCI, PubMed/PMC and ClinicalTrials.gov https://www.cancer.gov/about-cancer/treatment/types/stem-cell-transplant https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi https://clinicaltrials.gov/api/v2/studies NCI overview retrieved directly; established specialist-transplant context retained. PubMed query: (stem cell OR mesenchymal OR iPSC OR exosome OR hematopoietic transplantation) AND (trial OR safety OR adverse OR Parkinson OR diabetes OR spinal cord OR arthritis OR autoimmune OR cancer) AND (2026/11/10:2026/11/16[EDAT]). Retrieved all 496 matching XML records. Keyword triage selected 39 for further screening; not all 496 were fully appraised. Search matches include preclinical mechanisms, reviews and unrelated medicines, not 496 new clinical stem-cell trials. Registry query: (stem cell OR mesenchymal OR iPSC OR exosome) AND AREA[LastUpdatePostDate]RANGE[2026-11-10,2026-11-16]. Retrieved all 169 matching updated records across pages. These are updates, not necessarily new studies. Newly posted results flagged NCT07226752 (epcoritamab versus chemotherapy) and NCT04298658 (insomnia/pain in HIV); neither was selected as new evidence for a stem-cell intervention. The two specific trial records discussed above were independently retrieved despite not being updated in this week's window. Other literature screened: - PMID 43015648, DOI 10.1186/s12872-026-06371-x: CD133-positive cells as an adjunct to coronary bypass. Full publisher paper retrieved. Eleven studies, 495 participants; no consistent improvement in global ventricular function or major outcomes, with low/very-low certainty. Publisher date is August 26 despite new indexing this week. Kept as supporting evidence, not called a new November publication. https://pubmed.ncbi.nlm.nih.gov/43015648/ - PMID 43020901, DOI 10.1038/s41591-026-04712-z: transplant microbiome companion study of 304 participants; the primary association between engraftment microbiome diversity and one-year non-relapse mortality was not significant. Does not establish a microbiome cure or overturn the parent prophylaxis trial. Abstract-level screening. https://pubmed.ncbi.nlm.nih.gov/43020901/ - PMID 43004383, DOI 10.1186/s13287-026-05155-6: Hurler syndrome transplant systematic review; noncomparative evidence supports disease-modifying benefit while residual skeletal, sensory and cardiovascular disease and transplant risks persist. No new product approval. https://pubmed.ncbi.nlm.nih.gov/43004383/ - PMID 43035124: iPSC-derived immune-cell therapy review distinguishes early trials and conference/company reports from proven comparative benefit. Not a new broad iPSC treatment authorization. https://pubmed.ncbi.nlm.nih.gov/43035124/ - A November 11 Scientific Reports diabetes-vesicle lead describes mice and human cells in vitro, not treated human diabetes patients. Search-level lead, not promoted into clinical proof: https://www.nature.com/articles/s41598-026-71543-w - No new independently verified practice-changing Parkinson's, spinal-cord, autoimmune or arthritis authorization was selected. Prior Japan conditional approvals and last week's knee trial remain in the report. ### ISSCR and AAOS https://www.isscr.org/guidelines https://www.isscr.org/isscr-news https://www.isscr.org/public-policy https://www.orthoinfo.org/treatment/use-of-stem-cells-in-orthopaedics Guidelines/news retrieved via extraction; policy and AAOS directly. ISSCR guidelines still identify August 2025 version 1.2, a targeted embryo-model revision; not a new November clinical guideline. News includes intestinal stem-cell/high-fat-diet research and organizational notices, not a new clinical approval. Policy retains opposition to premature marketing. AAOS continues to emphasize uncertainty, risks and limited orthopedic evidence. These positions are not changed by a particular positive trial or cosmetic-product study. ### International regulation and clinic markets - EU: https://www.ema.europa.eu/en/news and https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-9-12-november-2026 retrieved. November 13 CHMP summary includes a positive opinion on generic Ruxolitinib Krka, including GVHD, but not a new stem-cell product approval. Recommendations are not European Commission marketing decisions. No country-table change selected. - UK: https://www.gov.uk/guidance/advanced-therapy-medicinal-products-regulation-and-licensing-in-uk retrieved. No new source-confirmed stem-cell authorization found in the current search; October Casgevy age extension already covered. - Japan: https://www.pmda.go.jp/english/review-services/reviews/approved-information/0004.html retrieved. March AMCHEPRY/RiHEART entries remain; translated index still displays original conditional Stemirac entry. https://www.pmda.go.jp/english/0006.html extraction yielded little usable content. Secondary recaps of an October panel decision do not verify final full authorization. No complete Japanese-language registry audit claimed. - Singapore: https://www.hsa.gov.sg/announcements/ retrieved. Followed today's new item: https://www.hsa.gov.sg/announcements/regulatory-updates--16-nov-2026-/ . Alternate extraction recovered the update after direct 403: a consultation on minor-variation checklists for chemical/biological therapeutic products and an electronic-product-information survey, not a new stem-cell approval or final cell-therapy rule. Draft consultation not treated as enacted policy. - Australia: https://www.tga.gov.au/news/safety-updates direct retrieval timed out; alternate extraction recovered the descriptive safety hub but not a complete current item list. Targeted November search returned unrelated listed-ingredient exclusivity and scheduling material. No new cell-specific action verified; current Australian safety coverage is limited, not certified complete. - Mexico: current Spanish searches were narrow/unhelpful, so broadened to official COFEPRIS alerts. Returned older COVID/stem-cell warnings and general alert hubs, not a verified November cell-clinic action. https://www.gob.mx/cofepris/acciones-y-programas/alertas-sanitarias-336947 and https://www.gob.mx/cofepris/documentos/alertas-sanitarias-de-medicamentos are search leads only in this run. - Panama: official-domain search returned framework documents and the 2026 transplant-vaccination schedule rather than a new cell-clinic policy. No new licensing/enforcement finding established. https://minsa.gob.pa/sites/default/files/publicaciones/marco_regulatorio_de_la_asn_2025_0.pdf was a search lead, not a newly verified rule. - Cayman: searches returned clinic and medical-tourism marketing, not a new regulator decision. FDA registration, local research permission and commercial treatment approval are different. No clinic licensing audit, price comparison or endorsement claimed. No price-table change justified. ### Public testimony A November 10 Korean entertainment-news lead describes actress Kim Mi-sook's cosmetic/fatigue impressions after treatment. The original video and treatment particulars were not independently authenticated. It remains anecdotal and was not judged sufficient for a new public report item: https://sportschosun.com/en/celebrity/2026-11-10/202611100100070700006547 . No celebrity endorsement or causal efficacy claim added. ## Article edits and non-changes Add November 16 subsection immediately after the medical caution; advance the evidence-check date. Include four bounded items above with primary links and a link to this note. The new items do not establish a changed stem-cell approval, price or country-level policy requiring a rewrite of the report's tables. Preserve original report and prior updates. Leave health.html unchanged because no new report/card is added. No stylesheet, image, homepage or clinic recommendation changes. Update article sitemap lastmod to November 16 and add this source note with the same date. Deploy only article, note and sitemap to the existing Hostinger shared-hosting directories, not KillerWolf. No DNS changes. Local pre-edit backup: _local-backups/stem-cells-2026-11-16/. Article, sitemap and Health page were byte-identical to remote files at preflight. DNS resolves to 195.35.15.247 and HTTPS headers identify Hostinger/LiteSpeed. Planned remote backup: domains/managingexpectations.net/backups/stem-cells-20261116/. Deployment-success evidence belongs in local remote-verification.json and live-verification.json, not assumed from this note. Local-only evidence folder: research/health/stem-cells-weekly-evidence-2026-11-16/. It contains source snapshots, retrieval status, PubMed XML/abstracts and registry JSON. Raw evidence may contain protocols; it is not deployed. Browser-vision tooling is not provided in this run; use parsed HTML, relative links, exact remote readbacks and live HTTP/content checks. Next checks: full BEACON responder and adverse-event tables; reconciled registry updates; diabetic-foot protocol and complete cohort reporting; longer controlled follow-up; scar-trial reporting clarification; FDA safety follow-up; final regulator decisions rather than repeated company/clinic claims. Medical boundary: education and source review only. Not medical advice, diagnosis, dosing, treatment guidance, clinic endorsement or an instruction to travel for therapy.